|Dr. Michael Ramroth||Chairman of the Management Board, CEO & CFO||1.11M||N/A||1961|
|Dr. Georg FloÃ||COO & Member of the Board of Management||882k||N/A||N/A|
|Dr. Monika Buttkereit||Head of Investor Relations||N/A||N/A||N/A|
|Dr. Christina Erb||Head of Corp. HR||N/A||N/A||N/A|
|Dr. Katrin BernÃ¶ster||Head of the Project Management Organisation||N/A||N/A||N/A|
|Mr. Peter Seith||Head of Quality Operations||N/A||N/A||N/A|
|Dr. JÃ¶rg SchÃ¼ttrumpf||Head of R&D||N/A||N/A||N/A|
|Dr. Wolfgang MÃ¶ller||Head of Devel. - Plasma Protein||N/A||N/A||N/A|
|Dr. Hermann Keuper||Sr. VP of Manufacturing||N/A||N/A||N/A|
Biotest Aktiengesellschaft develops, manufactures, and sells biological and biotechnological pharmaceutical products in Germany and internationally. It operates through Therapy, Plasma & Services, and Other segments. The company offers its products in haematology, clinical immunology, and intensive care medicine areas. Its products include Haemoctin and Vihuma for the treatment of haemophilia A acute therapy and prophylaxis; and Haemonine for haemophilia B acute therapy and prophylaxis. The company's products also comprise Cytotect for cytomegalovirus infections; Fovepta for hepatitis B prophylaxis in newborns; Hepatect for prophylaxis of hepatitis B re-infection; Intratect for primary immune and secondary antibody deficiency syndromes and autoimmune diseases, as well as neurological indications; IgG Next Genration for primary immune deficiency and immunothrombocytopenia; Varitect for the treatment of varicella zoster virus infections; Zutectra for hepatitis B re-infection prophylaxis after liver transplantation; and Cytotect 70(BT-094) for prevention of cytomegalovirus infection in the foetus during pregnancy with mother's CMV infection. In addition, it provides Albiomin for the treatment of blood volume depletion; Biseko to treat volume and serum protein depletion; Cofact for the treatment of clotting factors deficiency; Fibrinogen to treat congenital and acquired fibrinogen deficiency; Trimodulin for the community-acquired pneumonia; and Pentaglobin to treat bacterial infections. The company was formerly known as Biotest Serum-Institut GmbH and changed its name to Biotest Aktiengesellschaft in 1986. Biotest Aktiengesellschaft was founded in 1946 and is headquartered in Dreieich, Germany. Biotest Aktiengesellschaft is a subsidiary of Tiancheng International Investment Limited.
Biotest Aktiengesellschaft’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.